PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$26.35
−0.94%Aug 4, 2026, 20:01 UTC
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6 percent year-over-year increase, and highlighted continued execution of its 5x30 strategy with solid revenue growth, durable cashflows, advancing pipeline, and commercial partnerships.
Jul 1, 2026, 12:00 UTC
UnitedHealthcare now provides separate reimbursement for Pacira BioSciences' EXPAREL across outpatient settings.
Source:Jun 30, 2026, 00:00 UTC
Pacira BioSciences agreed to divest its Pacira CryoTech subsidiary and related cryoanalgesia device assets to Zimmer, Inc. for up to $140 million.
Source: